BR0110404A - Derivados de imidazopirimidina e derivados de triazolpirimidina - Google Patents

Derivados de imidazopirimidina e derivados de triazolpirimidina

Info

Publication number
BR0110404A
BR0110404A BR0110404-7A BR0110404A BR0110404A BR 0110404 A BR0110404 A BR 0110404A BR 0110404 A BR0110404 A BR 0110404A BR 0110404 A BR0110404 A BR 0110404A
Authority
BR
Brazil
Prior art keywords
optionally substituted
derivatives
triazolpyrimidine
imidazopyrimidine
alkyl
Prior art date
Application number
BR0110404-7A
Other languages
English (en)
Inventor
Takeshi Yura
Arnel B Concepcion
Gyoonhee Han
Makiko Hiraoka
Hiroko Katsumata
Norohiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Timothy B Lowinger
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0110404A publication Critical patent/BR0110404A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE IMIDAZOPIRIMIDINA E DERIVADOS DE TRIAZOLPIRIMIDINA". Um composto da fórmula (I) em que R^ 1^ é -X-R^ 4^ um resíduo heterocíclico opcionalmente substituído, um resíduo carbocíclico opcionalmente substituído ou uma porção de anel condensado opcionalmente substituída; X é CR^ 5^R^ 6^, O, S, SO, SO~ 2~ ou NR^ 7^; Y é CH ou N; R^ 2^ é H, uma C~ 1~-C~ 10~ alquila opcionalmente substituída, etc; R^ 3^ é uma arila opcionalmente substituída, ou uma heteroarila opcionalmente substituída, etc; R^ 4^ é uma arila opcionalmente substituída, uma heteroarila opcionalmente substituída, etc; R^ 5^, R^ 6^ e R^ 7^ podem ser idêticos ou diferentes e representam H, uma C~ 1~-C~ 10~ alquila opcionalmente substituída, etc. O composto tem uma excelente atividade anti-alérgica e semelhantes.
BR0110404-7A 2000-04-28 2001-04-17 Derivados de imidazopirimidina e derivados de triazolpirimidina BR0110404A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (1)

Publication Number Publication Date
BR0110404A true BR0110404A (pt) 2003-02-11

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110404-7A BR0110404A (pt) 2000-04-28 2001-04-17 Derivados de imidazopirimidina e derivados de triazolpirimidina

Country Status (38)

Country Link
US (1) US6911443B2 (pt)
EP (1) EP1278750B1 (pt)
JP (2) JP2001302667A (pt)
KR (1) KR20030009456A (pt)
CN (1) CN1263756C (pt)
AR (1) AR033367A1 (pt)
AT (1) ATE272639T1 (pt)
AU (1) AU783043B2 (pt)
BG (1) BG107166A (pt)
BR (1) BR0110404A (pt)
CA (1) CA2407531A1 (pt)
CZ (1) CZ20023551A3 (pt)
DE (1) DE60104671T2 (pt)
DK (1) DK1278750T3 (pt)
DO (1) DOP2001000151A (pt)
EE (1) EE200200606A (pt)
ES (1) ES2225546T3 (pt)
HK (1) HK1058362A1 (pt)
HR (1) HRP20020943A2 (pt)
HU (1) HUP0300846A2 (pt)
IL (1) IL151919A0 (pt)
MA (1) MA25746A1 (pt)
MX (1) MXPA02010579A (pt)
MY (1) MY141578A (pt)
NO (1) NO20025154D0 (pt)
NZ (2) NZ526221A (pt)
PE (1) PE20011287A1 (pt)
PL (1) PL358106A1 (pt)
PT (1) PT1278750E (pt)
RU (1) RU2306313C2 (pt)
SI (1) SI1278750T1 (pt)
SK (1) SK15332002A3 (pt)
SV (1) SV2001000416A (pt)
TR (1) TR200402300T4 (pt)
TW (1) TWI222974B (pt)
UA (1) UA72615C2 (pt)
WO (1) WO2001083485A1 (pt)
ZA (1) ZA200207676B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
JPWO2005037837A1 (ja) * 2003-10-17 2006-12-28 日本化薬株式会社 置換２−アミノ−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体及びその用途
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
PT1718649E (pt) * 2004-01-31 2009-08-06 Actimis Pharmaceuticals Inc Derivados de ácido imidazo[1,2-c]pirimidinilacético
EP1765825A1 (en) * 2004-06-25 2007-03-28 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
CA2599544A1 (en) 2005-02-28 2006-09-08 Japan Tobacco Inc. Novel aminopyridine compound with syk inhibitory activity
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0617241A2 (pt) * 2005-10-13 2016-11-08 Glaxo Group Ltd composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
LT3034075T (lt) * 2006-11-22 2018-11-26 Incyte Holdings Corporation Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai
EP2123654A4 (en) 2006-12-28 2011-05-11 Taisho Pharmaceutical Co Ltd pyrazolopyrimidine compound
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CN101874024A (zh) 2007-09-25 2010-10-27 艾克提麦斯医药品有限公司 作为crth2拮抗剂的2-s-苄基取代的嘧啶
SI2205569T1 (sl) 2007-09-25 2012-06-29 Actimis Pharmaceuticals Inc Alkiltio pirimidini kot crth2 antagonisti
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
EP3123864A1 (en) 2008-12-08 2017-02-01 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
AU2009325133B2 (en) 2008-12-08 2016-02-04 Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors
JP5744859B2 (ja) * 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
CA2786950C (en) 2009-12-23 2019-01-15 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
AU2011226689B2 (en) * 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
RU2012148246A (ru) * 2010-04-14 2014-05-20 Эррэй Биофарма Инк. 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
AU2012253885A1 (en) 2011-05-10 2013-10-31 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
WO2012154520A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052394A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
NZ627250A (en) * 2011-12-28 2016-04-29 Fujifilm Corp Novel nicotinamide derivative or salt thereof
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2931281B1 (en) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
WO2014100314A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
UA115815C2 (uk) 2013-07-30 2017-12-26 Гіліад Коннектікут, Інк. Склад на основі інгібіторів syk
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
MX2016007311A (es) 2013-12-04 2016-09-07 Gilead Sciences Inc Metodos para tratar canceres.
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015140054A1 (en) 2014-03-19 2015-09-24 Boehringer Ingelheim International Gmbh Heteroaryl syk inhibitors
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
EP3347353B1 (en) 2015-09-11 2019-07-17 Boehringer Ingelheim International GmbH Pyrazolyl-substituted heteroaryls and their use as medicaments
AU2018321264A1 (en) 2017-08-25 2020-02-27 Kronos Bio, Inc. Polymorphs of Syk inhibitors
MX2020004155A (es) 2017-10-19 2020-08-03 Bayer Animal Health Gmbh Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
WO2019099578A1 (en) * 2017-11-14 2019-05-23 Chidren's Medical Center Corporation Use of imidazopyrimidine for modulating human immune response
KR20200088397A (ko) 2017-11-14 2020-07-22 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
WO2019235570A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 グリオーマの処置剤および医薬組成物
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CA3130848A1 (en) 2019-02-22 2020-08-27 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
AU744939B2 (en) * 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
ATE401312T1 (de) * 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
CN1439009A (zh) 2003-08-27
AU6220401A (en) 2001-11-12
MY141578A (en) 2010-05-14
ES2225546T3 (es) 2005-03-16
PE20011287A1 (es) 2002-02-27
PL358106A1 (en) 2004-08-09
TR200402300T4 (tr) 2004-12-21
DE60104671T2 (de) 2005-12-29
EP1278750B1 (en) 2004-08-04
NO20025154L (no) 2002-10-25
RU2306313C2 (ru) 2007-09-20
KR20030009456A (ko) 2003-01-29
ZA200207676B (en) 2003-09-25
SV2001000416A (es) 2001-07-03
IL151919A0 (en) 2003-04-10
SK15332002A3 (sk) 2003-06-03
JP2001302667A (ja) 2001-10-31
MA25746A1 (fr) 2003-04-01
BG107166A (bg) 2003-06-30
CA2407531A1 (en) 2001-10-25
EP1278750A1 (en) 2003-01-29
MXPA02010579A (es) 2003-05-14
AU783043B2 (en) 2005-09-22
HRP20020943A2 (en) 2005-02-28
US6911443B2 (en) 2005-06-28
NZ526221A (en) 2005-01-28
NZ522241A (en) 2004-04-30
SI1278750T1 (en) 2005-02-28
NO20025154D0 (no) 2002-10-25
TWI222974B (en) 2004-11-01
JP2003535067A (ja) 2003-11-25
HK1058362A1 (en) 2004-05-14
UA72615C2 (en) 2005-03-15
DE60104671D1 (de) 2004-09-09
EE200200606A (et) 2004-04-15
US20040054179A1 (en) 2004-03-18
DK1278750T3 (da) 2004-11-22
CZ20023551A3 (cs) 2003-01-15
CN1263756C (zh) 2006-07-12
DOP2001000151A (es) 2002-05-15
AR033367A1 (es) 2003-12-17
ATE272639T1 (de) 2004-08-15
WO2001083485A1 (en) 2001-11-08
HUP0300846A2 (hu) 2003-08-28
PT1278750E (pt) 2004-11-30

Similar Documents

Publication Publication Date Title
BR0110404A (pt) Derivados de imidazopirimidina e derivados de triazolpirimidina
BR9806413A (pt) Composto e uso do mesmo
NL350077I2 (nl) Cyprosulfamide
ATE275134T1 (de) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
BR0316720A (pt) Derivados de piridazinona como inibidores de gsk-3beta
BR0208365A (pt) Derivados de 2-amino-propanol
BR0206738A (pt) Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase
DK0979821T3 (da) Tricykliske forbindelser
PT982992E (pt) Utilizacao de tienopirimidinas como fungicidas
MX9604398A (es) Derivados de sulfonamida.
DK0429627T3 (da) Derivater af quinolin-3-carboxanilider
BR0111780A (pt) Agente herbicida
BR0311410A (pt) Composto de piperidina
YU83993A (sh) Novi derivati piridon organske kiseline
EP1671957A4 (en) THIADIAZOLINDERIVATE
DE60228053D1 (de) Benzamidinderivate mit entzündungshemmender und immunsuppressiver wirkung
ES2188481T3 (es) Derivados de polinalbufina.
CO5080802A1 (es) Nuevos compuestos heterociclicos inhibidores de la fosfodiesteresa iv y su formulacion y uso como productos farmaceuticos
DE60037766D1 (de) Verfahren zur Herstellung von 2-Alkyl-3-aminothiophen Derivate und 3-Aminothiophen Derivate
DE69810373D1 (de) Pyrrolidin Derivate, Anti-ulcus und Antibakterielle Arzneimittel
DE60017374D1 (de) Antibakterielle mittel
DE60210504D1 (de) Funktionalisierte höhere diamantoide
DE60237652D1 (de) Variolinderivate und ihre Verwendung als Cytostatika
NO20004477L (no) Anvendelse av organiske karbonater for vasking av metalloverflater
EP1533312A4 (en) HETERO-BICYCLIC COMPOUNDS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.